tetano
Editor, Senior Moderator
Nat Med
. 2021 May 18.
doi: 10.1038/s41591-021-01370-1. Online ahead of print.
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Brian J Ward[SUP] 1 2 [/SUP], Philipe Gobeil[SUP] 3 [/SUP], Annie S?guin[SUP] 3 [/SUP], Judith Atkins[SUP] 3 [/SUP], Iohann Boulay[SUP] 3 [/SUP], Pierre-Yves Charbonneau[SUP] 3 [/SUP], Manon Couture[SUP] 3 [/SUP], Marc-Andr? D'Aoust[SUP] 3 [/SUP], Jiwanjeet Dhaliwall[SUP] 3 [/SUP], Carolyn Finkle[SUP] 3 [/SUP], Karen Hager[SUP] 3 [/SUP], Asif Mahmood[SUP] 3 [/SUP], Alexander Makarkov[SUP] 3 [/SUP], Matthew P Cheng[SUP] 4 [/SUP], St?phane Pillet[SUP] 3 [/SUP], Patricia Schimke[SUP] 3 [/SUP], Sylvie St-Martin[SUP] 3 [/SUP], Sonia Tr?panier[SUP] 3 [/SUP], Nathalie Landry[SUP] 5 [/SUP]
Affiliations
Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. Secondary outcomes in this ongoing study include safety and immunogenicity assessments up to 12 months after vaccination. Adults (18-55 years, n = 180) were randomized at two sites in Quebec, Canada, to receive two intramuscular doses of CoVLP (3.75 ?g, 7.5 ?g, and 15 ?g) 21 d apart, alone or adjuvanted with AS03 or CpG1018. All formulations were well tolerated, and adverse events after vaccination were generally mild to moderate, transient and highest in the adjuvanted groups. There was no CoVLP dose effect on serum NAbs, but titers increased significantly with both adjuvants. After the second dose, NAbs in the CoVLP + AS03 groups were more than tenfold higher than titers in Coronavirus 2019 convalescent sera. Both spike protein-specific interferon-? and interleukin-4 cellular responses were also induced. This pre-specified interim analysis supports further evaluation of the CoVLP vaccine candidate.
. 2021 May 18.
doi: 10.1038/s41591-021-01370-1. Online ahead of print.
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Brian J Ward[SUP] 1 2 [/SUP], Philipe Gobeil[SUP] 3 [/SUP], Annie S?guin[SUP] 3 [/SUP], Judith Atkins[SUP] 3 [/SUP], Iohann Boulay[SUP] 3 [/SUP], Pierre-Yves Charbonneau[SUP] 3 [/SUP], Manon Couture[SUP] 3 [/SUP], Marc-Andr? D'Aoust[SUP] 3 [/SUP], Jiwanjeet Dhaliwall[SUP] 3 [/SUP], Carolyn Finkle[SUP] 3 [/SUP], Karen Hager[SUP] 3 [/SUP], Asif Mahmood[SUP] 3 [/SUP], Alexander Makarkov[SUP] 3 [/SUP], Matthew P Cheng[SUP] 4 [/SUP], St?phane Pillet[SUP] 3 [/SUP], Patricia Schimke[SUP] 3 [/SUP], Sylvie St-Martin[SUP] 3 [/SUP], Sonia Tr?panier[SUP] 3 [/SUP], Nathalie Landry[SUP] 5 [/SUP]
Affiliations
- PMID: 34007070
- DOI: 10.1038/s41591-021-01370-1
Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. Secondary outcomes in this ongoing study include safety and immunogenicity assessments up to 12 months after vaccination. Adults (18-55 years, n = 180) were randomized at two sites in Quebec, Canada, to receive two intramuscular doses of CoVLP (3.75 ?g, 7.5 ?g, and 15 ?g) 21 d apart, alone or adjuvanted with AS03 or CpG1018. All formulations were well tolerated, and adverse events after vaccination were generally mild to moderate, transient and highest in the adjuvanted groups. There was no CoVLP dose effect on serum NAbs, but titers increased significantly with both adjuvants. After the second dose, NAbs in the CoVLP + AS03 groups were more than tenfold higher than titers in Coronavirus 2019 convalescent sera. Both spike protein-specific interferon-? and interleukin-4 cellular responses were also induced. This pre-specified interim analysis supports further evaluation of the CoVLP vaccine candidate.